Emergent BioSolutions Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Emergent BioSolutions Inc. on March 13, 2013, reporting an event that occurred on March 12, 2013. The filing addresses corporate governance changes regarding the appointment of a senior officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to personnel changes and does not contain financial performance data.
Material Changes
Effective April 1, 2013, the company elected Steven N. Chatfield, Ph.D., to the new position of Executive Vice President, Strategic Investments. Dr. Chatfield previously served as Executive Vice President, Biosciences since January 2012. In this new role, he will no longer be subject to reporting requirements under Section 16 of the Securities Exchange Act of 1934. The terms of his employment agreement remain unchanged.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on strategy, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Steven N. Chatfield, Ph.D., is transitioning to Executive Vice President, Strategic Investments effective April 1, 2013.
- Dr. Chatfield's new role exempts him from Section 16 reporting requirements.
- His existing employment agreement (filed as Exhibit 10.11 to the 2012 Form 10-K) remains in effect.
- No financial data or strategic outlook is included in this specific filing.